Monoclonal Antibodies to Legionella pneumophila: Possible Applications in Clinical Diagnostic Tests and Epidemiologic Investigations

Prevalence of Sequence Types among Clinical and Environmental Isolates of Legionella pneumophila Serogroup 1 in the United States from 1982 to 2012

“…More than 90% of the isolates associated with LD are Legionella pneumophila, and up to 84% of these are L. pneumophila serogroup 1 (Lp1) (3,4). Moreover, the majority of Legionella isolates associated with disease are Lp1 that react positively with monoclonal antibody 2 (MAb2) from the "Joly" MAb panel (5) or MAb3/1 from the "Dresden" MAb panel (6)(7)(8)(9)(10)(11).…”

Impact of the virulence-associated MAb3/1 epitope on the physicochemical surface properties of Legionella pneumophila sg1: An issue to explain infection potential?

“…Nine of them are the original clinical strains referenced in the Dresden panel of monoclonal antibodies (MAb) as described by Helbig et al [31] and Joly et al [12]: four MAb3/1 positive strains (Philadelphia, Allentown, Knoxville, Benidorm) and five MAb3/1 negative strains (Bellingham, Oxford, Camperdown, Heysham, OLDA) ( Table 1). The five other strains investigated in the current study were sampled during the epidemy in Nord Pas-de-Calais (France) and present the same genotype (Lens pulsotype ST15) [32]: one strain is from clinical origin (Lens C) and the four other strains from different hydrous environments (Lens A, B and D) and aerosols (Lens E) ( Table 1).…”

“…doi:10.1016/j.colsurfb.2010.08.040 of all culture-proven cases of community-acquired LD. In contrary, only 14.9-35% of Lp sg1 environmental isolates not associated with human infection react with MAb3/1 [4,5,[8][9][10][11][12]. Since this epitope is expressed on the majority of clinical isolates, it was designed as 'virulence-associated epitope' by Helbig et al [13].…”